Research News and Research

RSS

Study: Warburg effect promotes rapid cell proliferation and tumor growth

A team of scientists led by Professor Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory has discovered molecular factors in cancer cells that boost the production of an enzyme that helps alter the cells' glucose metabolism. The altered metabolic state, called the Warburg effect, promotes extremely rapid cell proliferation and tumor growth. Adrian Krainer, Ph.D.

23 Jan 2010

NCMHD awards Weill Cornell Medical College $8M for establishing CEDREC in New York City

Weill Cornell Medical College has established a new research center to improve medical care in ethnically diverse and medically underserved communities in New York City.

23 Jan 2010

Island Labs receives NHP approval for Stemcelex

Island Labs, a leader in natural dermatological products, has become the first company in Health Canada's history to receive Natural Health Product (NHP) approval.

23 Jan 2010

HSV-2 can reactivate throughout the genital tract

Genital herpes caused by a reactivation of herpes simplex virus type 2 (HSV-2) is generally treated as a lesion in one specific area of the genital region. A new study, however, finds that the virus can frequently reactivate throughout the genital tract, an important new concept that could help guide both HSV-2 treatment and prevention.

23 Jan 2010

IsoRay expands market awareness program by joining www.StockProfile.com

IsoRay, Inc., announced today that they have expanded their market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.

23 Jan 2010

Dark chocolates may ease emotional stress

There may well be another important reason for giving your sweetheart sweets for Valentine's Day besides the traditional romantic one: The "chocolate cure" for emotional stress is now getting new support from a clinical trial published online in ACS' Journal of Proteome Research. It found that eating about an ounce and a half of dark chocolate a day for two weeks reduced levels of stress hormones in the bodies of people feeling highly stressed.

23 Jan 2010

LifeNet Health to launch CardioGRAFT decell pulmonary patch with MATRACELL technology

LifeNet Health, a leading allograft bio-implant company, will nationally launch the CardioGRAFT® decell pulmonary patch with MATRACELL™ technology at the Society of Thoracic Surgeons annual meeting in Ft. Lauderdale, Fla., on January 24.

23 Jan 2010

Recent releases in global health

"Picture the situation in Haiti: families living on top of sewage-contaminated rubbish dumps, with no reliable sources of food and water and virtually no access to health care. This scenario depicts the situation in Haiti before the earthquake that catapulted this impoverished and conflict-ridden country into the international headlines,"

23 Jan 2010

PhRMA funds a two-year research initiative to evaluate the safety and benefits of existing drugs

The Pink Sheet recently reported that the Pharmaceutical Research and Manufacturers of America (PhRMA) and individual drug firms, through the Foundation for the National Institutes of Health, are funding a two-year public/private research initiative to evaluate the safety and benefits of drugs that are currently on the market.

23 Jan 2010

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

The U.S. Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.

23 Jan 2010

FDA approves fampridine-SR drug for treatment of multiple sclerosis

The Food and Drug Administration has approved the drug fampridine-SR for the treatment of multiple sclerosis. Researchers at the University of Rochester Medical Center (URMC) have been evaluating the effects of the drug in MS for more than 10 years- it is the first medication shown to enhance some neurological functions in people with the disease - and their efforts helped pave the way for today's action by the FDA.

23 Jan 2010

Ampyra receives FDA approval for improving walking in MS patients

The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

23 Jan 2010

Opinion: Haiti relief; WHO response to H1N1

An Economist editorial examines the relief and recovery efforts in Haiti and the "vital" importance of planning for rebuilding the country "before the world's generosity turns to cynicism. Fortunately there is a blueprint, drawn up by Haiti's government and presented to donors last year. It calls for investment to be targeted on infrastructure, basic services and combating soil erosion to make farmers more productive and the country less vulnerable to hurricanes. The pressing question is who should do it and how."

23 Jan 2010

USPTO issues new patent for Advaxis' intellectual property portfolio

The U.S. Patent and Trademark Office (USPTO) issued today patent 7,635,479, "Compositions and Methods for Enhancing the Immunogenicity of Antigens,” by Dr. Yvonne Paterson, et al, which is assigned to the Trustees of the University of Pennsylvania and licensed to Advaxis, Incorporated (OTCBB: ADXS).

22 Jan 2010

Workers combat hospital infections

CNN reports on efforts to combat hospital-acquired infections, which affect 1.7 million people each year and kill 99,000, while adding $28 billion to the nation's overall health care bill, according to federal research. "But there are signs of improvement. Pennsylvania, which requires the most extensive reporting of hospital-acquired infections, saw the annual rate for all infections drop 8 percent, according to the most recent figures available from the Pennsylvania Health Care Cost Containment Council."

22 Jan 2010

Health Policy Research: Covering young adults, Acos, wellness programs

Dependent Coverage Expansions: Estimating the Impact of Current State Policies - "With an estimated 29.3 percent of Americans age 19 to 29 lacking coverage, young adults are more likely to be uninsured than any other age group," the authors note.

22 Jan 2010

Data from GenVec's trial in esophageal cancer showcased at 2010 Gastrointestinal Cancer Symposium

GenVec, Inc. announced today that data from the Company's trial in esophageal cancer were presented at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010.

22 Jan 2010

NIH awards grants to develop new tobacco-related drug therapies

Four scientists at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center have been awarded more than $2.2 million from the National Institutes of Health (NIH) to research the effects of nicotine and develop new tobacco-related drug therapies.

22 Jan 2010

Progress in Anadys Pharmaceuticals' Phase II study of ANA598 announced

Anadys Pharmaceuticals, Inc. today announced that ANA598 dosing has been completed in the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.

22 Jan 2010

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).

22 Jan 2010